Abstract:Objective Hyperphenylalaninemia (HPA) is a genetic disease with the higher blood phenylalanine (Phe) level caused by the phenylalanine hydroxylase deficiency or the lower enzyme activity. Phenylketonuria (PKU) is the most common type of HPA. In this paper, the authors reviewed the clinical diagnosis, treatment and gene mutation detection of HPA in order to set up a preventive and therapeutic method for the disease. Method Seven hundred and sixty-nine subjects (454 males and 315 females, aged 0.8—27 years) with HPA from 28 provinces of China were enrolled in this study. Among them, 95 patients were diagnosed by the neonatal screening, 50 diagnosed by the high risk screening, the other 624 patients were diagnosed later. The family histories of all patients were investigated. The Phe concentration was determined with Guthrie bacterial inhibition assay and fluorescence method. The tetrahydrobiopterin deficiency (BH4D) was examined with the urinay pterin analysis and BH4 loading test. PKU patients were treated with the low or free Phe formula. The patients with BH4D were treated with BH4 and neurotransmitter precursors. The effects of the clinical treatment in patients with various HPA types were evaluated. The PKU gene was detected for mutations in 100 PKU patients. Prenatal diagnosis was carried out for 23 families with high risk PKU by using denaturing gradient gel electrophoresis (DGGE) and STR linkage analysis. Result (1) Of 769 patients 730 were diagnosed as having classic PKU, 27 patients as mild HPA and, 12 patients as BH4D whose urinary percentage of biopterin was (1.74±2.6) %, which was below the normal range. (2) Three hundred and thirty-eight PKU cases were treated with low or no phenylalanine milk. Of 95 patients, 71.6% of patients was diagnosed by neontal screening and 54.7% of 243 patients diagnosed later and the Phe could be better controlled with the treatment. (3) The intelligence quotient (IQ) evaluation was performed in 112 treated patients. The IQ of 55 patients diagnosed and treated after the neonatal screening was (78±22) score, IQ of 57 patients diagnosed later was (62±18) score. The IQ scores of these two groups were significantly different(P<0.001). IQ score of five BH4D patients was 70—80 after the treatment with combination of BH4 and neurotransmitter precursors. (4) Seventy-two patients went to school and 66.7% of them showed a middle or higher study score. (5) Five mutations, Arg111Ter, Arg241Cys, Arg243Glu, IVS6nt-1 and Arg252Gln, as well as a polymorphism of Val245Val were found in 100 PKU cases. (6)Prenatal diagnosis was performed for 23 families with high risk PKU, three fetuses were found to have PKU, and 20 fetuses were normal or heterozygotes which was confirmed by the neonatal screening for PKU after birth. Conclusion Both prenatal diagnosis and early diagnosis are effective methods for prevention and treatment of PKU. The early treatment and restriction of Phe level can minimize the mental retardation for HPA patients. Key words: Phenylketonurias; Neonatal screening; Biopterin; Genes; Mutation

Analysis of urine metabolites levels in children with hyperphenylalaninemia

Mutations in Patients with Hyperphenylalaninemia in Zhejiang, China

Quantification of Phenylalanine in the Brain of Patients with Hyperphenylalaninemia by 1H Magnetic Resonance Spectroscopy

Examining The Blood Amino Acid Status In Pretherapeutic Patients With Hyperphenylalaninemia

Efficacy and Safety of a Phenylalanine-Free Amino Acid-Based Enteral Formula (AA-PKU2) in 1-8 Year-Old Children with Phenylketonuria: a Prospective, Open, Self-Controlled and Multi-Center Study in China

Diagnosis, Treatment and Long-Term Following Up of 223 Patients with Hyperphenylalaninemia Detected by Neonatal Screening Programs

Clinical Phenotype of Different Hyperphenylalaninemia Patients

Efficacy and Safety of Phenylalanine-Free Amino Acid-Based Formula(aa-Pku1) on Chinese Infants with Phenylketonuria

Diagnosis, Treatment and Gene Detection in 769 Cases with Hyperphenylalaninemia

Study on 398 Neonates with Various Types of Hyperphenylalaninemia Detected by Neonatal Screening Program and 26 Year-Experiences of Diagnosis and Treatment for Hyperphenylalaninemia

Predictive value of fluorometric method and tandem mass spectrometry for hyperphenylalaninemia and its subtypes in China: A systematic review and meta‑analysis.

Tetrahydrobiopterin Loading Test in Differential Diagnosis among Hyperphenylalaninemia Patients

Clinical, genetic, and experimental research of hyperphenylalaninemia

Urinary Pterin Analysis in Screening of Tetrahydrobiopterin Def Iciency

Pterin Profiling in Serum, Dried Blood Spot, and Urine Samples Using LC-MS/MS in Patients with Inherited Hyperphenylalaninemia

Clinical and gene detection of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency

Influence of Age on ortho-Hydroxyphenylacetic Acid Excretion in Phenylketonuria and Its Genetic Variants

Clinical and genetic analysis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency

Screening for Tetrahydrobiopterin Deficiency among Hyperphenylalaninemia Patients in Southern China

[The Investigation of Differential Diagnostic Development and Incidence of Tetrahydrobiopterin Deficiency].

Quantification of derivatized phenylalanine and tyrosine in dried blood spots using liquid chromatography with tandem spectrometry for newborn screening of phenylketonuria